These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

259 related articles for article (PubMed ID: 33758147)

  • 1. Immune Checkpoint Inhibitor-related Guillain-Barré Syndrome: A Case Series and Review of the Literature.
    Janssen JBE; Leow TYS; Herbschleb KH; Gijtenbeek JMM; Boers-Sonderen MJ; Gerritsen WR; Westdorp H
    J Immunother; 2021 Sep; 44(7):276-282. PubMed ID: 33758147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Successful treatment of Guillain-Barré syndrome-like acute inflammatory demyelinating polyneuropathy caused by pembrolizumab with a combination of corticosteroid and immunoglobulins: a case report].
    Hashimoto R; Ueda T; Tsuji Y; Otsuka Y; Sekiguchi K; Matsumoto R
    Rinsho Shinkeigaku; 2020 Nov; 60(11):773-777. PubMed ID: 33115993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guillain-Barré Syndrome-Like Polyneuropathy Associated with Immune Checkpoint Inhibitors: A Systematic Review of 33 Cases.
    Li Y; Zhang X; Zhao C
    Biomed Res Int; 2021; 2021():9800488. PubMed ID: 34458371
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Atezolizumab-induced Guillain-Barré syndrome-like acute demyelinating polyneuropathy responsive to steroid therapy: a case report].
    Yamanaka N; Oishi M; Shimizu F; Koga M; Kanda T
    Rinsho Shinkeigaku; 2021 Oct; 61(10):653-657. PubMed ID: 34565748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Guillain-Barré syndrome in patients treated with immune checkpoint inhibitors.
    Fan Q; Hu Y; Wang X; Zhao B
    J Neurol; 2021 Jun; 268(6):2169-2174. PubMed ID: 33475824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune Checkpoint Inhibitor-Induced Guillain Barre Syndrome: A Single-Institution Case Report and Narrative Review.
    Idogun PO; Hafez-Khayyata S; Ezekwudo D
    Cureus; 2024 Jun; 16(6):e61489. PubMed ID: 38952584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Guillain-Barré Syndrome Related to Nivolumab: Case Report of a Patient With Urothelial Cancer and Review of the Literature.
    Kyriazoglou A; Liontos M; Papadopoulos C; Bilali A; Kostouros E; Pagoni S; Doumas K; Dimopoulos MA; Bamias A
    Clin Genitourin Cancer; 2019 Apr; 17(2):e360-e364. PubMed ID: 30612920
    [No Abstract]   [Full Text] [Related]  

  • 8. Guillain-Barré Syndrome Triggered by Immune Checkpoint Inhibitors: A Case Report and Literature Review.
    Supakornnumporn S; Katirji B
    J Clin Neuromuscul Dis; 2017 Dec; 19(2):80-83. PubMed ID: 29189553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical features and prognosis of patients with Guillain-Barré and acute transverse myelitis overlap syndrome.
    Guo F; Zhang YB
    Clin Neurol Neurosurg; 2019 Jun; 181():127-132. PubMed ID: 31039494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Severe Relapse of Vaccine-Induced Guillain-Barré Syndrome After Treatment With Nivolumab.
    Yuen C; Kamson D; Soliven B; Kramer C; Goldenberg F; Rezania K
    J Clin Neuromuscul Dis; 2019 Jun; 20(4):194-199. PubMed ID: 31135622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of Albumin Levels With Outcome in Intravenous Immunoglobulin-Treated Guillain-Barré Syndrome.
    Fokkink WR; Walgaard C; Kuitwaard K; Tio-Gillen AP; van Doorn PA; Jacobs BC
    JAMA Neurol; 2017 Feb; 74(2):189-196. PubMed ID: 28027337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond T cell toxicity - Intrathecal chemokine CXCL13 indicating B cell involvement in immune-related adverse events following checkpoint inhibition: A two-case series and literature review.
    Otto F; Seiberl M; Bieler L; Moser T; Kleindienst W; Wallner-Essl W; Koelblinger P; Wipfler P; Harrer A
    Eur J Neurol; 2024 Jul; 31(7):e16279. PubMed ID: 38556899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case Report: ICIs-induced Guillain-Barré syndrome recovered from mycophenolate mofetil.
    Ding M; Deng C; Liu X; Jiang S; Gao Y; Fan D; Zhou Y; He J; Liu C
    Front Immunol; 2023; 14():1132692. PubMed ID: 37223099
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A rare case of Miller Fisher variant of Guillain-Barr
    McNeill CJ; Fehmi J; Gladwin J; Price C
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31413049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
    Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
    J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of intravenous immunoglobulin retreatment amongst Guillain-Barré syndrome patients who poorly responded to initial IVIG cycle: a systematic review.
    Prado MB; Adiao KJB; Turalde CWR; Dasig DA
    Acta Neurol Belg; 2024 Aug; 124(4):1237-1250. PubMed ID: 38553651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case of Guillain-Barré Syndrome and Stevens-Johnson Syndrome/Toxic Epidermal Necrosis Overlap After Pembrolizumab Treatment.
    Oguri T; Sasada S; Shimizu S; Shigematsu R; Tsuchiya Y; Ishioka K; Takahashi S; Oki K; Kimura Y; Seki R; Hirose S; Nakamura M
    J Investig Med High Impact Case Rep; 2021; 9():23247096211037462. PubMed ID: 34344201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ramsay-Hunt syndrome and subsequent sensory neuropathy as potential immune-related adverse events of nivolumab: a case report.
    Sakoh T; Kanzaki M; Miyamoto A; Mochizuki S; Kakumoto T; Sato K; Uesaka Y; Kishi K
    BMC Cancer; 2019 Dec; 19(1):1220. PubMed ID: 31842803
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient characteristics and the effects of intravenous immunoglobulin in patients with Guillain-Barre syndrome.
    Guzey Aras Y; Tanik O; Dogan Güngen B; Kotan D
    Ideggyogy Sz; 2016 Nov; 69(11-12):389-395. PubMed ID: 29733556
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes of Serum IgG Dimer Levels after Treatment with IVIg in Guillain-Barré Syndrome.
    Svačina MKR; Röth P; Bobylev I; Sprenger A; Zhang G; Sheikh KA; Lehmann HC
    J Neuroimmune Pharmacol; 2019 Dec; 14(4):642-648. PubMed ID: 31515689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.